Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study

Background: The anti-programmed cell death protein-1 (PD-1) inhibitor is one of the second-line therapies for advanced hepatocellular carcinoma (HCC) after sorafenib failure. The goal of this study is to evaluate the feasibility and safety of ablation on the tumor in patients with advanced HCC who h...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Ning, Kong, Yanan, Li, Xiaoxian, Mu, Luwen, Deng, Haijing, Chen, Huiming, He, Meng, Lai, Jinfa, Li, Jibin, Tang, Hailin, Lin, Youen, Zhao, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581675/
https://www.ncbi.nlm.nih.gov/pubmed/33163408
http://dx.doi.org/10.3389/fonc.2020.580241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581675/
https://www.ncbi.nlm.nih.gov/pubmed/33163408
http://dx.doi.org/10.3389/fonc.2020.580241

Ejemplares similares